Literature DB >> 32721166

Utility of a Molecular Classifier as a Complement to HRCT to Identify Usual Interstitial Pneumonia.

Luca Richeldi1, Mary Beth Scholand2, David A Lynch3, Thomas V Colby4, Jeffrey L Myers5, Steve D Groshong6, Jonathan H Chung7, Sadia Benzaquen8, Steven D Nathan9, J Russell Davis10, Shelley L Schmidt11, Lars Hagmeyer12, David Sonetti13, Jurgen Hetzel14, Gerard J Criner15, Amy H Case16, Murali Ramaswamy17, Karel Calero18, Umair A Gauhar19, Nina M Patel20, Lisa Lancaster21, Yoonha Choi22, Daniel G Pankratz23, P Sean Walsh24, Lori R Lofaro25, Jing Huang22, Sangeeta M Bhorade25, Giulia C Kennedy26, Fernando J Martinez27, Ganesh Raghu28.   

Abstract

Rationale Usual interstitial pneumonia (UIP) is the defining morphology of idiopathic pulmonary fibrosis (IPF). Guidelines for IPF diagnosis conditionally recommend surgical lung biopsy (SLB) for histopathology diagnosis of UIP when radiology and clinical context are not definitive. A 'molecular diagnosis of UIP' in transbronchial lung biopsy (TBBx), the Envisia Genomic Classifier, accurately predicted histopathologic UIP. Objectives We evaluated the combined accuracy of the Envisia Genomic Classifier and local radiology in the detection of UIP pattern. Methods Ninety-six patients who had diagnostic lung pathology, as well as a TBBx for molecular testing with Envisia Genomic Classier, were included in this analysis. The classifier results were scored against reference pathology. UIP identified on HRCT as documented by features in local radiologists' reports was compared to histopathology. Measurements and Main Results In 96 patients, the Envisia classifier achieved a specificity of 92.1% [CI:78.6%-98.3%] and a sensitivity of 60.3% [CI:46.6%-73.0%] for histology-proven UIP pattern. Local radiologists identified UIP in 18 of 53 patients with UIP histopathology with a sensitivity of 34.0% [CI:21.5%-48.3%], and a specificity of 96.9% [CI:83.8 - 100]). In conjunction with HRCT patterns of UIP, the Envisia classifier results identified 24 additional UIP patients (sensitivity 79.2% specificity 90.6%). Conclusions In 96 patients with suspected ILD, the Envisia Genomic Classifier identified UIP regardless of HRCT pattern. These results suggest that recognition of a UIP pattern by the Envisia Genomic Classifier combined with HRCT and clinical factors in a multidisciplinary discussion may assist clinicians in making an ILD (especially IPF) diagnosis without the need for SLB.

Entities:  

Keywords:  idiopathic pulmonary fibrosis; molecular classifier; usual interstitial pneumonia

Year:  2020        PMID: 32721166     DOI: 10.1164/rccm.202003-0877OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  10 in total

Review 1.  Hypersensitivity pneumonitis: new concepts and classifications.

Authors:  Andrew Churg
Journal:  Mod Pathol       Date:  2021-09-16       Impact factor: 7.842

2.  A Handcrafted Radiomics-Based Model for the Diagnosis of Usual Interstitial Pneumonia in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Turkey Refaee; Benjamin Bondue; Gaetan Van Simaeys; Guangyao Wu; Chenggong Yan; Henry C Woodruff; Serge Goldman; Philippe Lambin
Journal:  J Pers Med       Date:  2022-02-28

3.  Performance of a diagnostic algorithm for fibrotic hypersensitivity pneumonitis. A case-control study.

Authors:  Sabina A Guler; Eva Wohlfarth; Sabina Berezowska; Thomas K Geiser; Lukas Ebner; Manuela Funke-Chambour
Journal:  Respir Res       Date:  2021-04-23

Review 4.  The histologic diagnosis of usual interstitial pneumonia of idiopathic pulmonary fibrosis. Where we are and where we need to go.

Authors:  Maxwell L Smith
Journal:  Mod Pathol       Date:  2021-08-31       Impact factor: 7.842

Review 5.  Contemporary Concise Review 2021: Interstitial lung disease.

Authors:  Cormac McCarthy; Michael P Keane
Journal:  Respirology       Date:  2022-05-05       Impact factor: 6.175

Review 6.  Diagnosing interstitial lung disease by multidisciplinary discussion: A review.

Authors:  Laura M Glenn; Lauren K Troy; Tamera J Corte
Journal:  Front Med (Lausanne)       Date:  2022-09-21

7.  Reliability of histopathologic diagnosis of fibrotic interstitial lung disease: an international collaborative standardization project.

Authors:  Robert Camp; Maxwell L Smith; Brandon T Larsen; Anja C Roden; Carol Farver; Andre L Moreira; Richard Attanoos; Raghavendra Pillappa; Irene Sansano; Alexandre Todorovic Fabro; Robert J Homer
Journal:  BMC Pulm Med       Date:  2021-06-01       Impact factor: 3.317

8.  Endobronchial Optical Coherence Tomography for the Diagnosis of Fibrotic Interstitial Lung Disease: A Light at the End of the Tunnel?

Authors:  Daniel-Costin Marinescu; Christopher J Ryerson
Journal:  Am J Respir Crit Care Med       Date:  2021-11-15       Impact factor: 21.405

Review 9.  The role of precision medicine in interstitial lung disease.

Authors:  Toby M Maher; Anoop M Nambiar; Athol U Wells
Journal:  Eur Respir J       Date:  2022-02-03       Impact factor: 33.795

Review 10.  Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response.

Authors:  Willis S Bowman; Gabrielle A Echt; Justin M Oldham
Journal:  Front Med (Lausanne)       Date:  2021-05-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.